Systems Biology of Gastrointestinal and Related Diseases

Study Purpose

This is a longitudinal observational study on patients with gastrointestinal and related disease. The study will be conducted for at least 10 years, following each participant over time, as they either go through relapses and remissions, or progression of their disease.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

No
Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.


An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.


Searching Both is inclusive of interventional and observational studies.

Observational
Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion criteria.

  • - Any patient 18 years old or older that schedules a visit to WAGI clinics or endoscopy center.
  • - Able to use electronic communications.
  • - Able to communicate in English.
  • - Consent to participate in the study.

Exclusion Criteria:

- None

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.

NCT05579444
Phase

Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Viome
Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Momchilo Vuyisich
Principal Investigator Affiliation Viome
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Industry
Overall Status Recruiting
Countries United States
Conditions

The disease, disorder, syndrome, illness, or injury that is being studied.

Ulcerative Colitis, Crohn Disease, Obesity, Colon Polyp, Eosinophilic Esophagitis, GERD, Gastro Esophageal Reflux, Barrett Esophagus, Esophageal Cancer, Gastritis, Gastric Ulcer, Duodenal Ulcer, Intestinal Metaplasia, Gastric Cancer, Lymphocytic Colitis, Microscopic Colitis, Celiac Sprue, IBS, Irritable Bowel Syndrome, SIBO, NAFLD, Gallstone Disease
Additional Details

This is a longitudinal, observational study whose main goal is to identify the human and microbial determinants of gastrointestinal diseases. Molecular and metadata will be collected from a large study population at multiple time points. Machine learning will be applied to all data, and models will be evaluated for development of novel diagnostic and therapeutic tools.

Arms & Interventions

Arms

: Ulcerative Colitis

Participants with ulcerative colitis.

: Crohn's Disease

Participants with Crohn's disease.

: Obesity

Participants that are obese.

: Colon Polyps

Participants with colon polyps.

: Eosinophilic esophagitis

Participants with Eosinophilic esophagitis

: Gastroesophageal Reflux Disease (GERD)

Participants with Gastroesophageal Reflux Disease (GERD).

: Gastritis

Participants with gastritis.

: Gastric ulcers

Participants with gastric ulcers.

: Duodenal ulcers

Participants with duodenal ulcers.

: Intestinal metaplasia

Participants with intestinal metaplasia (risk factor for esophageal cancer).

: Gastric Cancer

Participants with gastric cancer.

: Lymphocytic/Microscopic Colitis

Participants with Lymphocytic/Microscopic Colitis.

: Celiac Sprue

Participants with Celiac Sprue.

: Irritable Bowel Syndrome (IBS)

Participants with IBS.

: Small intestinal bacterial overgrowth (SIBO)

Participants with SIBO.

: Non-alcoholic Fatty Liver Disease (NAFLD)

Participants with NAFLD.

: Gallstone disease

Participants with Gallstone disease.

Interventions

Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

Viome Life Sciences, Bothell, Washington

Status

Recruiting

Address

Viome Life Sciences

Bothell, Washington, 98011

Site Contact

Mory Mehrtash

studies@viome.com

425-300-6933

The content provided by the Celiac Disease Foundation on clinical trials is for informational purposes only and is not a substitute for medical consultation with your healthcare provider. We do not recommend or endorse any specific study and you are advised to discuss the information shown with your healthcare provider. While we believe the information presented on this website to be accurate at the time of writing, we do not guarantee that its contents are correct, complete, or applicable to any particular individual situation. We strongly encourage individuals to seek out appropriate medical advice and treatment from their physicians. We cannot guarantee the availability of any clinical trial listed and will not be responsible if you are considered ineligible to participate in a given clinical trial. We are also not liable for any injury arising as a result of participation. For a full description of terms please refer to: Privacy Policy and Terms of Use.